
Ymmunobio AG
Basel, Switzerland · ymmunobio.com
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Ymmunobio AG is a preclinical biotech company based in Basel, Switzerland and Princeton, New Jersey. It develops novel antibody-based therapies for solid tumors, with a focus on NPTXR-targeted programs and companion diagnostics.
Their website has a general contact form; we send your quote request through it.
What they offer
Antibody-based solid tumor therapeutics development
Develops first-in-class antibody-based therapies for solid tumors.
Dual-payload ADC development
Develops anti-NPTXR antibody-drug conjugates using a third-generation 4+4 linker-payload architecture with MMAF and exatecan.
Radio ligand therapy development
Develops RLT programs using 177 Lu and 161 Tb for NPTXR-targeted imaging and therapy.
Bispecific T-cell engager development
Develops next-generation bi-specific T-cell engagers that redirect T cells to NPTXR-positive tumors.
Trispecific T-cell engager development
Develops next-generation tri-specific T-cell engagers with CD3 and CD28 components for NPTXR-positive tumors.
Companion diagnostics development
Develops diagnostics including liquid biopsy, PET imaging, and SPECT imaging to support patient screening.
What they work on
- Modalities
- Small molecule, Antibody, Bispecific, ADC, Peptide, Oligonucleotide, Cell therapy
- Therapeutic areas
- solid tumors, oncology
- Sites
- Basel, Switzerland · Princeton, USA
- Address
- featuring 177 Lu and 161 Tb for NPTXR-targeted imaging (RLT-Dx) and thera
- Founded
- 2012
Similar labs. Aurigene Pharmaceutical Services, ORF Biologics, Sparx BIO, 3C Therapeutics
Found in a contract services directory. Listing built from ymmunobio.com. Work here? Claim this listing.